Jessica Meng
Patrimonio netto: 8 M $ in data 31/08/2026
Patrimonio netto: 8 M $ in data 31/08/2026
Jessica Meng is Chief Commercial Officer at CareDx, Inc. since 2024.
Former roles include Vice President-Marketing at Veracyte, Inc. from 2018 to 2020 and Chief Commercial Officer at Delfi Diagnostics, Inc. Education includes an undergraduate degree from the University of Pennsylvania and an MBA from The Wharton School of the University of Pennsylvania.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
CAREDX, INC. 0,31% | 12/09/2026 | 161.599 ( 0,31% ) | 8 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CAREDX, INC. | Corporate Officer/Principal | 12/09/2024 |
| Società | Posizione | Fine |
|---|---|---|
| VERACYTE, INC. | Vendite & Marketing | 01/05/2020 |
Delfi Diagnostics, Inc.
Delfi Diagnostics, Inc. BiotechnologyHealth Technology Develops AI-powered liquid biopsy tests using fragment omics technology to help detect cancer early through simple blood draws | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
CareDx, Inc.
CareDx, Inc. Medical SpecialtiesHealth Technology Manufactures diagnostic test kits and provides related testing services | Health Technology |
Veracyte, Inc.
Veracyte, Inc. Medical SpecialtiesHealth Technology Discovers, develops and commercializes diagnostic products & biopharmaceutical services | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Delfi Diagnostics, Inc.
Delfi Diagnostics, Inc. BiotechnologyHealth Technology Develops AI-powered liquid biopsy tests using fragment omics technology to help detect cancer early through simple blood draws | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale